Biosimilars and the Challenge of “Product Hopping”
Humira has fallen off its throne. For years, it was the world’s top-selling drug, generating more than $20 billion in annual sales at its peak in 2021 for AbbVie. But then, Humira’s patent ran out, paving the way for a flood of competitive alternatives. AbbVie knew this was coming, and in a surprising shift, Skyrizi […]
